PRESS RELEASE published on 11/25/2025 at 18:33, 4 months 5 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma communique sur son activité et sa trésorerie du 3ème trimestre 2025. Chiffre d’affaires consolidé de 3,06 M€ et trésorerie de 2,8 M€ au 30 septembre 2025 Chiffre D’affaires Biopharmaceutique Trésorerie ABIONYX Pharma Trimestre 2025
PRESS RELEASE published on 11/25/2025 at 18:33, 4 months 5 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 4 months 19 days ago ABIONYX Pharma en discussions avancées avec l'IHU SEPSIS Partenariat Stratégique ABIONYX Pharma Sepsis IHU SEPSIS Biomédicaments
BRIEF published on 11/12/2025 at 07:05, 4 months 19 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
PRESS RELEASE published on 11/12/2025 at 07:00, 4 months 19 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce des discussions stratégiques avancées avec l’IHU SEPSIS, 1er centre mondial dédié au sepsis, pour une alliance structurante et transformante dans le traitement global du sepsis Alliance ABIONYX Pharma Sepsis Discussions Stratégiques IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 5 months 10 days ago Validation génétique de l'ApoA-I dans le sepsis par ABIONYX Pharma ABIONYX Pharma Thérapies Innovantes Apolipoprotéine A-I Septicémie Validation Génétique
BRIEF published on 10/21/2025 at 18:54, 5 months 10 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 5 months 10 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce une validation historique dans la revue NATURE confirmant la causalité génétique de l'apolipoprotéine A-I (ApoA-I) dans le sepsis. Une avancée majeure dans le traitement de la septicémie Validation Historique ABIONYX Pharma Nature Septicémie Causalité Génétique
PRESS RELEASE published on 10/21/2025 at 18:49, 5 months 10 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
BRIEF published on 10/06/2025 at 15:00, 5 months 26 days ago Franchissement de seuil par la Caisse des dépôts et consignations dans ABIONYX PHARMA Droits De Vote Franchissement De Seuil CDC Bpifrance ABIONYX
Published on 04/01/2026 at 15:10, 13 minutes ago A2Z Announces Audited Full-Year 2025 Financial Results
Published on 04/01/2026 at 15:00, 23 minutes ago Karbon-X Named Official Sustainability Partner of the Detroit Red Wings and Detroit Tigers
Published on 04/01/2026 at 14:30, 53 minutes ago Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
Published on 04/01/2026 at 14:00, 1 hour 23 minutes ago Dateline Completes A$50M Institutional Placement to Advance Colosseum
Published on 04/01/2026 at 14:00, 1 hour 23 minutes ago Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Published on 04/01/2026 at 15:17, 5 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 04/01/2026 at 15:11, 11 minutes ago Form 8.3 - The Vanguard Group, Inc.: A consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited
Published on 04/01/2026 at 08:00, 7 hours 23 minutes ago Transfert du contrat de liquidité aupres de Natixis Oddo BHF
Published on 04/01/2026 at 08:00, 7 hours 23 minutes ago Résultats annuels 2025 - ANR par action en hausse de + 8,1 % à 97,10 € - Fonds propres consolidés : 740 M€
Published on 03/31/2026 at 20:08, 19 hours 14 minutes ago SMTPC - Communiqué sur les résultats annuels 2025
Published on 03/31/2026 at 19:05, 20 hours 17 minutes ago SFPI GROUP: implementation of a new liquidity contract
Published on 03/31/2026 at 19:05, 20 hours 17 minutes ago Groupe SFPI : mise en oeuvre d'un nouveau contrat de liquidité
